These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35040209)

  • 1. Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).
    Buhmann C; Lezius S; Pötter-Nerger M; Gerloff C; Kuhle J; Choe CU
    Mov Disord; 2022 Feb; 37(2):435-436. PubMed ID: 35040209
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".
    Aamodt WW; Chen-Plotkin AS
    Mov Disord; 2022 Feb; 37(2):436-437. PubMed ID: 35150470
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
    Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
    Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
    Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
    J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Author response to Wang et al. Blood neurofilament light chain in Parkinson's disease: A biological marker for prediction of cognitive impairment?
    Sampedro F; Kulisevsky J
    Parkinsonism Relat Disord; 2020 Aug; 77():159. PubMed ID: 32586750
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
    Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
    J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood neurofilament light chain in Parkinson's disease: A biological marker for prediction of cognitive impairment?
    Wang H; Wang W; Shi H; Han L
    Parkinsonism Relat Disord; 2020 Aug; 77():157-158. PubMed ID: 32563681
    [No Abstract]   [Full Text] [Related]  

  • 9. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K
    Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study.
    Choe CU; Petersen E; Lezius S; Cheng B; Schulz R; Buhmann C; Pötter-Nerger M; Daum G; Blankenberg S; Gerloff C; Schwedhelm E; Zeller T
    Parkinsonism Relat Disord; 2021 Apr; 85():5-10. PubMed ID: 33636481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment.
    Huang X; Ng SY; Chia NS; Acharyya S; Setiawan F; Lu Z; Tan YJ; Ng E; Wen MC; Ng ASL; Tay KY; Au WL; Tan EK; Tan LC
    Mov Disord; 2018 Dec; 33(12):1970-1971. PubMed ID: 30345542
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
    Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neurofilament light chain predicts future freezing of gait in Parkinson's disease.
    Kim R; Jeon B
    Parkinsonism Relat Disord; 2021 Oct; 91():102-104. PubMed ID: 34555572
    [No Abstract]   [Full Text] [Related]  

  • 16. Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Wilke C; Dos Santos MCT; Schulte C; Deuschle C; Scheller D; Verbelen M; Brockmann K; von Thaler AK; Sünkel U; Roeben B; Bujac S; Metzger FG; Maetzler W; da Costa AN; Synofzik M; Berg D
    Mov Disord; 2020 Jul; 35(7):1233-1238. PubMed ID: 32338403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study.
    Pellecchia MT; Savastano R; Moccia M; Picillo M; Siano P; Erro R; Vallelunga A; Amboni M; Vitale C; Santangelo G; Barone P
    J Neural Transm (Vienna); 2016 Dec; 123(12):1399-1402. PubMed ID: 27682634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity.
    Huxford B; Haque T; Joseph AB; Simonet C; Gallagher D; Budu C; Dobson R; Noyce A
    Mov Disord; 2022 Feb; 37(2):427-428. PubMed ID: 34643295
    [No Abstract]   [Full Text] [Related]  

  • 19. On the correlation between serum Cystatin C and Parkinson's disease in the Chinese population: a promising biomarker?
    Yang CG; Cai SM; Liu CY; Chen C
    J Integr Neurosci; 2021 Jun; 20(2):349-357. PubMed ID: 34258933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
    Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
    Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.